Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 12:03 save search
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
Published: 2021-03-08 (Crawled : 12:03) - globenewswire.com
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 12.38%
H: 2.33%
C: -3.86%
phase 1 renal trial phase 1b phase 2b cell carcinoma
Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases
Published: 2021-03-02 (Crawled : 12:03) - globenewswire.com
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: 0.0%
H: 3.09%
C: -3.3%
disease phase 1 trial phase 3 phase 2
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.5 -1.33% -1.35% 370K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
ANNX | $4.435 -3.27% -3.38% 1.4M
|
Health Technology
|
| O: 3.13%
H: 7.26%
C: -0.37%
phase 2 trial
Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT
Published: 2021-02-25 (Crawled : 12:03) - globenewswire.com
CMRX | $0.94 3.98% 3.83% 360K
|
Health Technology
|
| O: 0.69%
H: 6.44%
C: 4.1%
covid results trial topline covid-19
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation
Published: 2021-02-25 (Crawled : 12:03) - globenewswire.com
BTAI | $2.56 -1.16% -1.17% 240K
|
Health Technology
|
| O: 0.84%
H: 5.05%
C: -4.02%
treatment phase 2 trial
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Published: 2021-02-22 (Crawled : 12:03) - globenewswire.com
NVAX | $3.9 0.26% 0.26% 2.8M
|
Health Technology
|
| O: -3.56%
H: 3.41%
C: -8.55%
covid vaccine phase 3 trial enroll
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
Published: 2021-02-22 (Crawled : 12:03) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: -49.54%
H: 23.53%
C: 10.29%
disease results phase 3 trial topline
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
Published: 2021-02-19 (Crawled : 12:03) - globenewswire.com
AVXL | $3.8 -6.63% -7.11% 1.7M
|
Health Technology
|
| O: 1.03%
H: 1.49%
C: -1.65%
life science trial anavex
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
Published: 2021-02-04 (Crawled : 12:03) - globenewswire.com
BTAI | $2.56 -1.16% -1.17% 240K
|
Health Technology
|
| O: 0.0%
H: 1.27%
C: -1.65%
cancer prostate cancer trial ongoing symposium
Whitmore and Shell Lubricants Announce Definitive Agreement to Form Joint Venture to Provide Industrial Products and Services to North America Rail and United States Mining Customers
Published: 2021-01-22 (Crawled : 12:03) - globenewswire.com
CSWI | $234.23 0.77% 0.77% 98K
|
Process Industries
|
| O: -1.22%
H: 2.58%
C: 2.31%
trial
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
Published: 2021-01-19 (Crawled : 12:03) - globenewswire.com
ACRS | $1.235 0.41% 0.4% 650K
|
Health Technology
|
| O: 138.95%
H: 41.99%
C: 34.02%
positive trial rheumatoid arthritis topline phase 2b
Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis
Published: 2021-01-14 (Crawled : 12:03) - globenewswire.com
ORGO | $2.865 2.69% 2.62% 330K
|
Finance
|
| O: 32.7%
H: 7.9%
C: -2.57%
phase 3 trial osteoarthritis enroll designation rmat
Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica
Published: 2021-01-11 (Crawled : 12:03) - globenewswire.com
CARA | $0.69 -5.73% -6.07% 360K
|
Health Technology
|
| O: 0.0%
H: 4.81%
C: 2.63%
trial treatment phase 2
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
Published: 2021-01-07 (Crawled : 12:03) - globenewswire.com
PRQR | $1.86 -2.11% -2.15% 180K
|
Health Technology
|
| O: 0.47%
H: 6.78%
C: 5.61%
trial treatment enroll
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
Published: 2021-01-06 (Crawled : 12:03) - globenewswire.com
ZNTL | $12.55 -1.26% -1.27% 680K
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -6.83%
trial
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Published: 2021-01-06 (Crawled : 12:03) - globenewswire.com
OCUP | $1.675 -3.74% -3.88% 240K
|
Health Technology
|
| O: 0.0%
H: 1.32%
C: -4.64%
phase 3 trial enroll
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
Published: 2020-12-22 (Crawled : 12:03) - globenewswire.com
RYTM A | $38.11 -0.88% -0.89% 440K
|
Health Technology
|
| O: -5.08%
H: 1.68%
C: 0.54%
results phase 3 positive trial topline setmelanotide syndros
Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
ANNX | $4.435 -3.27% -3.38% 1.4M
|
Health Technology
|
| O: -2.28%
H: 0.97%
C: -7.1%
trial phase 2 phase 2/3 syndros
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
LIFE | $1.625 2.2% 2.15% 260K
|
Health Technology
|
| O: 0.74%
H: 8.56%
C: 3.91%
trial phase 1b phase 2b enroll pharma
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.